CommercialPrior AuthMedium impact
Anzemet (dolasetron)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
Effective date
Jun 3, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their Anzemet (dolasetron) policy requiring prior authorization for all prescriptions, with new criteria including age restrictions (2+ years), failure/intolerance to ondansetron within 180 days, and use only for emetogenic chemotherapy or radiation therapy. The policy clarifies that drug samples cannot be used to satisfy medical necessity requirements.
Action Required
By June 3, 2025: Billing and clinical teams must update workflows to obtain prior authorization for all Anzemet (dolasetron) prescriptions. Providers must document: patient age 2+ years, emetogenic chemotherapy/radiation therapy indication, ondansetron failure/intolerance within past 180 days, no contraindications, and FDA-approved dosing. Update EMR templates to capture required documentation. Claims without prior auth will be denied.